Amendment No. 4 to Collaborative Research and License Agreement



  
 Exhibit 10.1

 [********] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. 

AMENDMENT NO. 4 TO 
 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT 
 This Amendment No. 4 to
Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the Collaborative Research and License Agreement entered into as of December 27,
2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”), as amended by
Amendment No. 1 dated November 10, 2006, Amendment No. 2 effective July 8, 2009, and Amendment No. 3 effective April 30, 2010 (the “Agreement”). Capitalized terms used herein and not otherwise defined
shall have the meanings ascribed to them in the Agreement. 
 WHEREAS AstraZeneca and Targacept desire to amend, in accordance
with Section 17.6 of the Agreement, various aspects of the Agreement to provide (i) terms on which Targacept would [********] a human clinical trial of Ispronicline as a treatment for AD and (ii) for certain other rights and
obligations with respect to the Development of Ispronicline as a treatment for AD. 
 NOW, THEREFORE, in consideration of the
mutual covenants contained herein and for other good and valuable consideration, AstraZeneca and Targacept, intending to be legally bound, hereby agree as follows: 
 1. Section 5.10.1 of the Agreement is hereby amended by deleting the text thereof in its entirety and replacing it with the following: 
 “Except (a) in the conduct of the Research Program or any Additional Research Program as provided in Sections 4.1, 4.3, 4.4 and 4.8, (b) subject to Section 5.10.2(c)(1), for the
identification, research and development of potential Back-Up Option Compounds (which, for purposes of clarity, are Additional Compounds with respect to the corresponding Option Compound Candidate Drugs) that have not yet themselves become Option
Compound Candidate Drugs, (c) as provided in Section 5.2.2, (d) for the Targacept Development Activities, and (e) for the [********] the TRGT Ispronicline AD Trial (as defined in Section 5.14) and activities
incidental thereto, notwithstanding anything else in this Agreement to the contrary, AstraZeneca shall have the sole and exclusive right during the Term to research, develop, manufacture, commercialize and otherwise Exploit all Collaboration
Compounds, Candidate Drugs and Products (including to Develop Candidate Drugs and Commercialize Products) in the Territory for use in the Field and in Schizophrenia.” 
 2. The Agreement is hereby amended by adding the following new Section 5.14. 
 “5.14
TRGT Ispronicline AD Trial. 
 (a) Contingent upon the execution by the Parties of the Agreement relating to
AZD3480 Clinical Study in AD dated on or about September 28, 2010 (the “TRGT Ispronicline AD Trial Agreement”) and subject to the other terms of this Agreement, AstraZeneca shall, and hereby does, grant to Targacept and its
Affiliates a non-exclusive, royalty-free, worldwide license during the Term, without the right to grant sublicenses (except as reasonably necessary in connection with the 







 
engagement by Targacept of any Third Party to conduct the TRGT Ispronicline AD Trial (as defined below) or any activity incidental thereto), under AstraZeneca Technology and AstraZeneca Patent
Rights and AstraZeneca’s interest in Joint Technology and Joint Patent Rights solely to conduct as contemplated by the TRGT Ispronicline AD Trial Agreement a human clinical trial of Ispronicline as a treatment for AD (the “TRGT
Ispronicline AD Trial”) and activities incidental thereto. 
 (b) Notwithstanding any terms of the Agreement to the
contrary (including Section 5.3 (Product Development Plans) and Section 6.4 (R&D Funding)), unless otherwise expressly provided in the TRGT Ispronicline AD Trial Agreement or agreed in writing by the Parties, all costs and expenses
incurred by Targacept to conduct the TRGT Ispronicline AD Trial shall be borne by Targacept and shall not be reimbursed by AstraZeneca. 
 (c) Unless and until AstraZeneca in its sole discretion were to determine [********] to conduct another Clinical Trial of Ispronicline in AD at a [********] (the “Internal AZ AD
Advancement Action”): (i) the TRGT Ispronicline AD Trial shall not be [********] for purposes of [********]; and (ii) consistent with clause (i), AstraZeneca shall not be required to [********] for
[********] based on [********] in the TRGT Ispronicline AD Trial. For clarity and without limitation of any [********] that [********] under the Agreement (including [********]), if the Internal AZ AD Advancement
Action occurs, AstraZeneca shall thereupon be required to [********]. For purposes of this Section 5.14(c) and Section 5.14(d), a [********] is [********] if such [********], be reasonably expected to
[********] or, together with [********]; provided that the designation of [********] shall not create any implication that [********]. 
 (d) Notwithstanding anything in the Agreement to the contrary, including the provisions of [********], and regardless of [********] the TRGT Ispronicline AD Trial, AstraZeneca
[********]; provided that (i) if AstraZeneca [********], or [********] Targacept [********], AstraZeneca’s [********] shall thereafter apply in accordance with such Section [********] and
(ii) nothing in this Section 5.14(d) is intended to modify [********] with respect to Ispronicline and ADHD or any other Primary Indication.” 
 3. The Agreement is hereby amended by adding the following new Section 6.1A. 
 “6.1A
AD Program Achievement Payments. AstraZeneca shall pay Targacept the following non-refundable and non-creditable fees (each, an “AD Program Achievement Payment”) in immediately available funds: 

[********] Five Hundred Thousand Dollars (US $500,000) on or before October 5, 2010; 

[********] within [********] Business Days after receipt of a Targacept invoice therefor after [********];

 [********] within [********] Business Days after receipt of a Targacept invoice therefor after [********]

 [********] within [********] Business Days after receipt of a Targacept invoice therefor after
[********]. 
 As used in this Section 6.1(A), the term [********] means the [********] and is
[********].” 

  
 2 








  
 4. Section 8.1.3 of the Agreement
is hereby amended by (a) deleting the “and” before clause (E) in the proviso at the end thereof and (b) adding the following to the end of such proviso (before the period): 

“; and (F) to conduct (or have conducted) the TRGT Ispronicline AD Trial and activities incidental thereto” 

5. Except as expressly amended by this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. 

[remainder of page intentionally left blank] 

  
 3 








  
 IN WITNESS WHEREOF AstraZeneca and
Targacept have executed this Amendment as of the respective dates set forth below. 
  

									
	TARGACEPT, INC.	 		 	ASTRAZENECA AB (publ.)
					
	By:	 	 /s/ J. Donald deBethizy
	 		 	By:	 	 /s/ Anders Burén

					
	Name:	 	 J. Donald deBethizy
	 		 	Name:	 	 Anders Burén

					
	Title:	 	 President & CEO
	 		 	Title:	 	 Authorised Signatory

					
	Date:	 	 September 28, 2010
	 		 	Date:	 	 September 28, 2010



  

[Signature Page to Amendment No. 4]